Allen Institute
The Allen Institute is a non-profit bioscience research organization based in Seattle, Washington, founded in 2003 by Paul G. Allen, the late co-founder of Microsoft, and his sister Jody Allen to accelerate foundational discoveries in biology and advance human health.[1] With a 270,000-square-foot headquarters in Seattle's South Lake Union biotechnology hub, the institute conducts large-scale, open-access research, openly sharing data, tools, and resources to catalyze global scientific progress.[2] The institute's work spans several specialized divisions, including the Allen Institute for Brain Science, which maps brain cell types and circuits to understand neural function; the Allen Institute for Cell Science, focused on decoding cellular organization and behavior; the Allen Institute for Immunology, investigating immune system dynamics in health and disease; the Paul G. Allen Frontiers Group, which funds innovative, high-risk projects across biosciences; the Seattle Hub for Synthetic Biology, developing cellular recording technologies; and the Brain and Consciousness Program, studying the neural basis of consciousness.[1] Additional efforts, such as the Allen Institute for Neural Dynamics established in 2021, explore the computational principles underlying complex behaviors like decision-making and memory.[3] These divisions employ multidisciplinary teams of neuroscientists, cell biologists, immunologists, engineers, and data scientists to tackle fundamental questions in life sciences.[1] Notable achievements include the inaugural Allen Brain Atlas, a comprehensive, three-dimensional gene expression map of the adult mouse brain completed in 2006, which serves as a foundational resource for neuroscience research.[4] The institute's open science approach has influenced studies on conditions like Alzheimer's disease, cancer, and immune disorders, with ongoing projects generating multimodal cell censuses and advanced imaging tools shared freely with the global community. In 2025, the institute launched the Brain Knowledge Platform, integrating 34 million standardized brain cell datasets to accelerate neuroscience research, and the CellScapes initiative to understand fundamental principles of cellular state change.[1][5][6] Under the leadership of Board Chair Jody Allen, the Allen Institute continues to drive bold, collaborative science, supported by a mix of philanthropic, government, and private funding.[1]Overview
Mission and Founding
The Allen Institute is a nonprofit bioscience research organization dedicated to understanding the principles that govern life and advancing health through creative, multi-dimensional teams focused on bioscience frontiers.[7] Founded in 2003 by philanthropist Paul G. Allen, co-founder of Microsoft, and his sister Jody Allen, the institute began with an initial endowment of $100 million specifically targeted at brain science research.[1][8] From its inception, the Allen Institute emphasized accelerating scientific discovery through large-scale, team-based projects that assemble multidisciplinary experts, contrasting with traditional models reliant on individual grant-funded research.[8][1] Paul G. Allen's vision for the institute was shaped by his extensive philanthropy in technology and conservation, aiming to democratize science by producing open-access data resources that enable global collaboration and catalyze breakthroughs in health and disease understanding.[1][8][9]Location and Facilities
The Allen Institute is headquartered in Seattle, Washington, at 615 Westlake Avenue North in the South Lake Union neighborhood.[10][11] This location positions the institute within a vibrant biotechnology hub, facilitating proximity to academic and industry partners such as the University of Washington.[7] The institute's facilities include a 270,000-square-foot state-of-the-art headquarters building completed in 2015, with additional leased space of approximately 21,000 square feet in the nearby Dexter Yard life sciences campus since September 2022.[7][12][13] This infrastructure includes specialized laboratories for imaging, computation, and animal research, such as wet and dry labs, an electron microscopy area, and vertical vivarium suites with animal holding rooms and behavioral training spaces on multiple floors.[14][15] Key amenities encompass advanced microscopy suites for techniques like confocal and electron microscopy, high-performance computing clusters supported by a dedicated data center, and collaborative spaces that integrate lab, office, and meeting areas to promote interdisciplinary interactions.[14][15][16] In January 2024, the institute launched the Seattle Hub for Synthetic Biology, a collaborative initiative with the Chan Zuckerberg Initiative and the University of Washington, utilizing facilities in the South Lake Union area to develop cellular recording technologies.[17] Sustainability is a core aspect of the facilities, with the headquarters achieving LEED Gold certification from the U.S. Green Building Council for its energy-efficient design, including abundant natural light, high-performance building systems, and green practices.[18][16] These features support the institute's long-term operational efficiency while minimizing environmental impact.[18]History
Establishment
The Allen Institute for Brain Science was launched on September 16, 2003, as the organization's inaugural program, marking the beginning of a nonprofit dedicated to accelerating neuroscience research through large-scale, open-access initiatives.[8] Founded by philanthropist Paul G. Allen in Seattle, the institute aimed to tackle fundamental questions about brain function by creating comprehensive public resources, starting with an ambitious mapping project.[8] To lead the scientific efforts, the institute recruited Dr. Allan Jones as its founding scientific director, who joined as one of the first employees and oversaw the assembly of an initial team that rapidly expanded to include approximately 75 additional scientists, technologists, and support staff over the ensuing years.[19][8] This multidisciplinary group was structured around short-term, milestone-driven contracts—initially three years—to ensure focused progress on defined goals, reflecting Allen's preference for targeted philanthropy over open-ended funding.[20] The first major project, the Allen Brain Atlas, sought to create a comprehensive gene expression atlas of the adult mouse brain by mapping the activity of all approximately 20,000 genes across its structure.[20] Supported by a $100 million seed commitment from Paul G. Allen specifically for this three-year endeavor, the project emphasized high-throughput technologies and open data sharing to produce a three-dimensional, web-accessible resource.[8] Remarkably, the Allen Brain Atlas was completed ahead of schedule and publicly released in September 2006, providing neuroscientists worldwide with a foundational tool that has since been cited thousands of times and integrated into numerous studies.[4] This early success validated the institute's model of team-based, goal-oriented research, setting the stage for future expansions while adhering to the principle of milestone accountability in Allen's broader philanthropic vision, with commitments exceeding $500 million across the institute's programs through additional major gifts for new divisions.[21]Key Milestones and Expansions
In 2007, the Allen Institute expanded the Allen Brain Atlas with new datasets, including the first human cortex gene expression data and results from a sleep study, enhancing the open-access resource for neuroscience research.[22] The institute expanded its scope in 2014 with the launch of the Allen Institute for Cell Science, funded by a $100 million commitment from founder Paul G. Allen to develop predictive models of human cell function and organization.[23] In 2016, the Paul G. Allen Frontiers Group was established with an initial $100 million investment from Allen, aimed at supporting innovative, high-risk bioscience projects to address fundamental questions in biology.[24] The Allen Institute for Immunology was formally established in 2018, seeded by a $125 million gift from the late Paul G. Allen, to map and understand immune system dynamics in health and disease.[25] That same year, on October 15, Paul G. Allen passed away from complications of non-Hodgkin's lymphoma at age 65, leading to his sister Jody Allen assuming the role of board chair to guide the institute's ongoing mission.[26] In 2021, the institute established the Allen Institute for Neural Dynamics within its Brain Science division to investigate real-time brain activity, circuits, and behavior, building on earlier mapping efforts with a focus on dynamic processes.[3] By 2023, the MindScope program transitioned into the Brain and Consciousness Program to deepen exploration of neural mechanisms underlying perception, decision-making, and awareness, while the Seattle Hub for Synthetic Biology was launched in partnership with the Chan Zuckerberg Initiative and the University of Washington, committing $75 million collectively to engineer cells as biological recorders for studying disease progression.[27][17] In 2025, the institute announced its Next Generation Leaders cohort, selecting eight early-career researchers to foster diverse talent in bioscience frontiers through networking, mentorship, and collaborative opportunities over three years.[28]Research Divisions
Brain Science Division
The Brain Science Division of the Allen Institute, established in 2003 as the institute's foundational program, is dedicated to characterizing brain cell types at scale to advance understanding of the brain's structure and function.[1][8] This division employs a multidisciplinary approach integrating genetics, advanced imaging techniques, and computational methods to generate detailed maps of cellular diversity across the brain.[29] By focusing on molecular and spatial profiling, the division aims to uncover the cellular basis of neural organization, supporting broader insights into cognition and behavior.[29] A cornerstone project is the Allen Brain Cell (ABC) Atlas, which serves as an open platform for visualizing and analyzing multimodal single-cell data from the entire mammalian brain, encompassing both mouse and human specimens.[30][31] This atlas integrates transcriptomic, epigenetic, and spatial datasets to delineate cell types hierarchically across brain regions, enabling researchers to explore cellular identities and their distributions.[32] Complementing this, the division has made significant contributions to the BRAIN Initiative Cell Census Network (BICCN), a collaborative effort funded by the NIH to create comprehensive cell type atlases for human, mouse, and nonhuman primate brains.[33][34] Through BICCN, Allen Institute researchers have led the integration of large-scale datasets from transcriptomics, morphology, and physiology, producing multimodal classifications that catalog thousands of cell types and their properties.[35][36] Current initiatives extend these mapping efforts to investigate brain development, evolutionary adaptations, and disease mechanisms via multi-species comparisons, revealing conserved and divergent cellular features across mammals. In April 2025, researchers unveiled the first complete 3D map of an entire mammalian brain at cellular resolution, led by the Allen Institute in collaboration with 21 other institutions.[37][29] For instance, comparative analyses in the ABC Atlas and BICCN datasets highlight how cell type diversity evolves and how disruptions may contribute to neurological disorders.[38] The division's work adheres to open science principles, making all data publicly accessible to facilitate global research.[29] The division comprises over 200 scientists, encompassing neuroscientists, engineers, computational biologists, and data specialists organized into specialized teams for projects, imaging, and technology development.[39][40] This team science model fosters integrated expertise to tackle complex challenges in brain mapping.[41]Cell Science Division
The Allen Institute for Cell Science was launched in 2014 with a $100 million commitment from philanthropist Paul G. Allen to advance the understanding of human cell biology.[42] The division's primary aim is to create integrated, predictive models of human cells by studying their behavior in three dimensions and over time, utilizing stem cell-derived models such as induced pluripotent stem cells (iPSCs) to simulate cellular processes in health and disease.[43] This approach seeks to uncover the organizational principles governing cell function, enabling predictions of cellular responses to perturbations relevant to conditions like cancer and regenerative medicine.[1] Key projects include the Allen Cell Explorer, an open data portal that provides interactive 3D visualizations of cellular structures and dynamics in human iPSCs, allowing researchers to explore organelle organization and interactions at high resolution.[44] Another major initiative is the development of comprehensive mitotic cell imagery datasets, which capture the dynamic changes in 15 key cellular structures across the five stages of cell division using nearly 40,000 high-resolution images from fluorescently tagged stem cell lines.[45] These datasets, including computational models and additional imagery, serve as a baseline for studying mitosis and its dysregulation in diseases.[46] The division's current focus involves integrating multi-omics data—encompassing genomics, transcriptomics, proteomics, and imaging—to predict how cells respond to disease states, particularly in cancer and neurodegeneration.[43] This work emphasizes holistic cell models that link molecular profiles to observable behaviors, facilitating the identification of therapeutic targets.[42] To support the scientific community, the division offers open-access resources such as the Allen Cell & Structure Segmenter, a Python-based toolkit for 3D segmentation of intracellular structures in fluorescence microscopy images using machine learning algorithms.[47] Additional tools include software for image analysis, data visualization, and simulation, all freely available to promote reproducible research in cell biology.[48]Immunology Division
The Allen Institute for Immunology was established in 2018 with a $125 million endowment from philanthropist Paul G. Allen to probe the complexities of the human immune system in health and disease.[25] The division employs advanced single-cell technologies to investigate immune cell diversity and intercellular interactions, aiming to uncover fundamental principles that govern immune regulation during infection, autoimmunity, and cancer.[49] By generating comprehensive datasets from healthy individuals and patients, researchers create reference atlases of immune states, such as the Human Immune Health Atlas, which profiles over 16 million peripheral blood immune cells across ages 25 to 90 to establish baselines for variability in immune function.[50] A major focus includes mapping immune responses to COVID-19, where single-cell analyses reveal distinct patterns of T-cell and B-cell activation that correlate with disease severity and recovery, helping explain why some infections resolve asymptomatically while others lead to severe outcomes or long COVID.[51] In autoimmune diseases, the division dissects mechanisms in lupus and rheumatoid arthritis (RA) through multi-omic profiling of patient samples, identifying early breakdowns in immune tolerance—such as heightened inflammatory signaling in pre-symptomatic RA individuals—before clinical symptoms emerge, which could enable preventive interventions.[52] For instance, studies show systemic inflammation and lymphocyte activation precede joint pain in RA, with altered immune cell subsets detectable years in advance.[53] Current efforts center on developing predictive models for immunotherapy efficacy in cancers, particularly blood cancers like multiple myeloma, by integrating pre- and post-treatment immune profiles to forecast responses to checkpoint inhibitors and stem cell transplants.[54] These models draw on tumor microenvironment data to pinpoint immune evasion tactics, such as suppressed T-cell infiltration, aiding personalized treatment strategies for high-relapse malignancies.[25] Methodologically, the division leverages high-throughput sequencing for deep immune cell phenotyping and spatial transcriptomics to map immune landscapes within tissues, revealing how cellular positioning influences function in contexts like chronic inflammation or tumor niches.[55] This approach, combined with computational tools, supports the creation of open-access resources for broader scientific use.[49]Neural Dynamics Division
The Allen Institute for Neural Dynamics was launched in 2021 as a dedicated division within the Allen Institute, focusing on elucidating real-time neural circuit dynamics in the mammalian brain through advanced imaging and electrophysiology techniques.[3] This division investigates how neural signals propagate through circuits to interpret environmental cues and drive behaviors, using mice as primary models to parallel human cognitive processes such as foraging and economic decision-making.[56] Led by Karel Svoboda, the division employs a multidisciplinary approach to trace activity patterns at both cellular and network levels, aiming to uncover the mechanisms underlying complex behaviors.[3] Key projects emphasize functional analysis in behaving animals, including the use of two-photon calcium imaging to monitor cell-type-specific activity during task learning and novelty processing in mice.[57] For instance, the Cell Types & Learning initiative combines longitudinal in vivo imaging with spatial transcriptomics to reveal how distinct neuronal populations adapt during learning tasks.[57] Complementary efforts, such as the Dynamic Routing project, explore models of decision-making and sensory processing by studying task-switching behaviors, where circuits reconfigure to route information flexibly.[58] Another notable project, Credit Assignment During Learning, employs optical connection-mapping and brain-computer interfaces to examine synaptic updates that support learning, providing insights into how errors are assigned and corrected in neural networks.[59] These initiatives have contributed to high-impact findings, such as the synaptic architecture of layer 5 excitatory neurons in mouse visual cortex, which informs sensory processing models. Current research links recurring circuit motifs to cognitive functions, including attention and learning, by analyzing multi-regional interactions like thalamic modulation of cortical activity.[58] The Brain-Wide Neuromodulation project, for example, dissects subclasses of neuromodulator neurons and their roles in modulating learning and decision-making across brain regions.[58] Technologies central to this work include custom optogenetics tools for precise perturbation of neuronal activity, as demonstrated in synaptic mapping studies, and computational simulations to model network-level computations.[59] Advanced methods like Neuropixels probes for electrophysiology and three-photon microscopy for deeper imaging further enable high-resolution tracking of voltage dynamics in behaving mammals, as detailed in recent publications. These approaches prioritize scalable, open-access tools to advance understanding of neural dynamics' behavioral impacts.[56]Frontiers Group
The Paul G. Allen Frontiers Group, a division of the Allen Institute, was initiated in 2016 with an initial $100 million commitment from philanthropist Paul G. Allen to catalyze high-risk, high-reward research in biosciences.[60] The group invests in external researchers and teams worldwide who tackle fundamental unsolved biological questions, aiming to generate transformative insights that reshape understanding of human biology and disease.[61] Through its funding programs, it supports exploratory work that prioritizes bold innovation over incremental advances, fostering diverse perspectives from scientists at various career stages.[62] The group's primary focus areas encompass origins of life, cellular reprogramming, and novel disease therapies, among broader bioscience frontiers such as membrane biophysics and organelle dynamics. For instance, it has provided grants for studies on synthetic organelles to explore cellular compartmentalization and communication, enabling new approaches to engineering biological systems. Similarly, funding has supported investigations into extremophile biology, using resilient organisms like nematodes to model adaptations in changing environments and inform therapeutic strategies.[63] These efforts align with the institute's open science principles by requiring data sharing to accelerate collective progress.[61] Awards are distributed via programs like the Allen Distinguished Investigators, which provide $1–1.5 million over three years to individual or small-team projects, and Allen Discovery Centers, offering up to $20 million over eight years for larger initiatives.[62] The selection process involves peer-reviewed open calls and competitions that evaluate proposals based on their potential for paradigm-shifting impact, with rigorous scientific review emphasizing feasibility, novelty, and interdisciplinary potential. Since inception, the group has awarded over $10 million in multiple cohorts to address such challenges, scaling support to match project ambition.[64]Seattle Hub for Synthetic Biology
The Seattle Hub for Synthetic Biology was launched in 2023 as a collaborative initiative between the Allen Institute, the Chan Zuckerberg Initiative, and the University of Washington to advance synthetic biology applications in health research.[17] This hub focuses on engineering synthetic gene networks that enable the study and manipulation of biological functions, particularly by developing technologies to record cellular histories over time and link genetic changes to disease processes.[65] These networks function as programmable "recorders" within cells, capturing dynamic events such as gene expression or environmental exposures to provide insights into developmental biology and immunology.[66] Key projects at the hub include the design of minimal genomes to explore essential genetic elements and their rearrangements in mammalian cells, as pursued by the Pinglay Lab, which aims to map genome consequences for more efficient synthetic constructs.[67] Additionally, efforts involve developing gene drives and related synthetic tools for disease modeling, building on gene-editing advancements to simulate pathological gene propagation and test therapeutic interventions.[68] These projects emphasize scalable, high-fidelity systems that integrate CRISPR-based editing with synthetic circuits to model complex diseases like cancer or immune disorders.[69] Current goals center on creating tools for precise gene editing in complex tissues, such as brain or immune organs, to enable in vivo recording and manipulation at single-cell resolution. In March 2025, the hub received a $10 million grant from the Washington Research Foundation to train the next generation of synthetic biologists and accelerate technology development.[70] This includes refining promoter libraries and gRNA scaffolds for robust mammalian genome engineering, facilitating next-generation synthetic gene networks.[71] The hub's specialized facilities support these aims through dedicated labs for DNA synthesis, protein engineering, and high-throughput screening, allowing rapid prototyping and validation of synthetic constructs across millions of cells.[65]Brain and Consciousness Program
The Brain and Consciousness Program at the Allen Institute investigates the neural underpinnings of awareness in mammals by elucidating the physical substrate of consciousness in the brain.[72] Evolved from the MindScope Program in 2023, it integrates behavioral observations, advanced imaging techniques, and theoretical modeling to probe the mechanisms underlying conscious experience.[73] This approach builds on prior large-scale neural recording efforts to explore how brain activity gives rise to subjective perception and awareness.[27] Key projects within the program focus on studying perceptual states in mice and non-human primates through large-scale neural recordings. In mice, researchers employ high-density electrophysiological probes, such as Neuropixels, to capture activity across cortical and subcortical regions during sensory tasks, revealing how visual stimuli are processed in behaving animals.[74] For non-human primates, similar high-density recordings enable brain-wide mapping of neural responses to perceptual inputs, providing insights into the distributed nature of sensory awareness.[75] These efforts leverage standardized platforms like the Allen Brain Observatory to ensure reproducible, high-throughput data collection. The program's current emphasis involves developing theories that connect thalamocortical interactions to conscious experience, examining how synchronized activity between the thalamus and cortex contributes to perceptual binding and awareness.[72] Researchers utilize virtual reality environments to immerse mice in controlled sensory scenarios, allowing precise manipulation of visual and behavioral contexts to dissect conscious processing.[76] Complementing this, AI-assisted data analysis techniques facilitate behavioral phenotyping by automating the identification of subtle patterns in neural and movement data, enhancing the interpretation of large datasets from these experiments.[77]Scientific Approach
Open Science Principles
The Allen Institute has upheld open science as a foundational principle since its inception, committing to the unrestricted release of all validated data, tools, and scientific findings to the global research community. This policy originated with the launch of the Allen Mouse Brain Atlas in 2006, which mapped gene expression across the mouse brain and was made freely accessible online without requiring registration or fees, provided proper attribution is given. By prioritizing immediate dissemination upon validation, the Institute bypasses traditional publication timelines, enabling researchers worldwide to build upon its outputs without delay.[78][79] This approach yields significant benefits, including accelerated scientific progress and enhanced reproducibility in neuroscience and related fields. For instance, datasets from the Institute have garnered over 10,000 citations in peer-reviewed publications, demonstrating their widespread adoption and influence on subsequent discoveries. The policy fosters a collaborative ecosystem where open access reduces barriers to entry, allowing diverse investigators to integrate Allen Institute resources into their work efficiently.[78] Implementation occurs through dedicated, user-friendly data portals such as the Allen Brain Map and the Allen Cell Explorer, which provide interactive access to curated resources. These platforms incorporate standardized metadata protocols to ensure consistency, interoperability, and ease of use across datasets, facilitating seamless integration with other scientific tools. This infrastructure supports the Institute's nonprofit mission by promoting transparency and collective advancement.[78][80] To address potential challenges like intellectual property concerns, the Allen Institute leverages its nonprofit status and employs open licensing models that encourage sharing while protecting the integrity of the work. This framework mitigates risks associated with proprietary restrictions, allowing commercial and academic users alike to derive value without legal encumbrances. Such strategies have enabled the Institute to sustain its open science ethos across its research divisions.[78]Multidisciplinary Collaboration
The Allen Institute employs a multidisciplinary approach to research, assembling cross-disciplinary teams that integrate expertise from biologists, physicists, mathematicians, engineers, and data scientists from the outset of projects. This team-based methodology emphasizes collaborative problem-solving, where diverse perspectives address complex bioscience challenges, such as understanding cellular and neural systems at scale. By blending experimental and computational disciplines, these teams foster innovation through shared goals and structured interactions, including regular meetings and symposia that prioritize group progress over individual achievements.[81][82] Examples of this integration include joint laboratory environments where computational modelers collaborate closely with experimentalists to incorporate real-time data analysis into ongoing experiments, enabling iterative refinements and rapid hypothesis testing. Such setups facilitate seamless workflows, allowing teams to leverage tools like advanced imaging and modeling software developed in-house. This internal synergy ensures that theoretical insights inform practical experimentation without delays, enhancing the efficiency of large-scale investigations.[81][83] To support this collaborative culture, the Institute offers extensive internal training programs for its over 800 staff members, including workshops on AI applications in biology, advanced imaging techniques, and ethical considerations in scientific practice. These initiatives, such as hands-on sessions with open-source modeling tools and physiology data collection methods, promote lifelong learning and skill development across roles. By equipping employees with interdisciplinary competencies, the programs strengthen team cohesion and adaptability.[82][84][83] The outcomes of this multidisciplinary collaboration include accelerated problem-solving, as demonstrated by hybrid wet-lab and dry-lab workflows that combine robotic automation with computational simulations for streamlined data processing. This approach has enabled the Institute to produce high-impact resources more efficiently, contributing to foundational advances in bioscience while supporting open data practices that further internal team dynamics.[81][1]Leadership and Governance
Board of Directors
The Board of Directors of the Allen Institute provides high-level oversight and stewardship to ensure the organization advances its mission in biomedical research through open science and innovation.[85] Chaired by Jody Allen since 2018 following the death of co-founder Paul G. Allen, the board guides strategic direction and long-term sustainability.[86] The board comprises 13 members with diverse expertise in science, finance, philanthropy, business, and ethics, enabling balanced decision-making on research priorities and resource allocation.[85] Responsibilities include strategic planning, financial oversight, and approval of major initiatives, such as the establishment of new research divisions.[85] Key members bring specialized knowledge: for instance, A. Paul Alivisatos, a nanoscientist and former director of the National Science Foundation, contributes to scientific strategy; Gerald Rubin, executive director of the Howard Hughes Medical Institute's Janelia Research Campus, offers insights in neuroscience; and Aviv Regev, president and head of Genentech Research and Early Development, provides expertise in genomics and computational biology.[85] In finance and philanthropy, Matt McIlwain, managing director at Madrona Venture Group, supports investment decisions, while Phyllis J. Campbell, an independent board director and former JPMorgan Chase executive, advises on governance.[85] Bioethicist Alta Charo, from the University of Wisconsin, ensures ethical considerations in research advancements.[87] The full current composition includes:| Member | Affiliation/Expertise |
|---|---|
| A. Paul Alivisatos | University of Chicago (nanotechnology, science policy) |
| Jody Allen | Board Chair; Allen Family Philanthropies (philanthropy, business) |
| Margaret Anderson | Deloitte Consulting LLP (healthcare consulting, nonprofit leadership) |
| Joanne Berger-Sweeney | Trinity College (education, business) |
| Phyllis J. Campbell | Independent Board Director and Adviser (finance, philanthropy) |
| Alta Charo | University of Wisconsin (bioethics, law) |
| Thomas L. Daniel | University of Washington (biology, engineering) |
| Carla DewBerry | K&L Gates (law, corporate governance) |
| Steve Hall | Cercano Management (investment management) |
| Matt McIlwain | Madrona (venture capital, technology) |
| Aviv Regev | Genentech (genomics, computational biology) |
| Gerald Rubin | HHMI Janelia Research Campus (neuroscience, genetics) |
| Michael P. Stryker | University of California, San Francisco (neuroscience) |